Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Kyntra Bio, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics for serious unmet medical needs, with a primary focus on oncology and rare diseases. Headquartered in San Francisco, California, and incorporated in 1993, the company today centers its efforts on targeted therapies for cancer and anemia-related conditions. A key program is FG-3246, a first-in-class antibody-drug conjugate targeting CD46, being evaluated for metastatic castration-resistant prostate cancer, alongside FG-3180, a related PET imaging biomarker designed to visualize CD46-positive tumors and support patient selection. Kyntra Bio also develops roxadustat, an oral small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase, used for the treatment of anemia in chronic kidney disease and investigated in myelodysplastic syndromes. Through internal R&D and collaboration agreements with partners such as Astellas Pharma and AstraZeneca, Kyntra Bio occupies a specialized role in the healthcare sector, aiming to provide differentiated, mechanism-based therapies across global markets.